Trial of radioactive drug for gastric and pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests a radioactive drug that targets a protein called Claudin 18.2 found on some stomach and pancreatic cancer cells. Researchers will track where the drug goes in your body and how it exits, to see if it's a safe and effective way to deliver radiation directly to tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have stomach (gastric) cancer or pancreatic cancer that has been confirmed by a biopsy
- Your cancer cells have a specific protein called Claudin 18.2 on their surface
- At least one of your tumors must have this Claudin 18.2 protein
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan to see if a new imaging agent can find a protein called claudin 18.2 on cancer cells in pancreatic, stomach, or gastroesophageal junction cancers. The scan may help doctors better see the cancer and guide treatment decisions.
This early-stage trial tests a new drug called SNA014 for pancreatic cancer. The drug targets a specific protein marker (Claudin-18.2) on cancer cells, and researchers want to see if it's safe and effective for patients whose tumors have this marker.
This Phase 2 study tests new combination treatments for advanced stomach or stomach-esophagus junction cancer that cannot be removed by surgery. It may help people whose tumors are positive for a marker called Claudin18.2, which the study uses to choose who can receive the treatment.
This trial tests a new treatment called DaRT, which places tiny radioactive devices directly into your pancreatic tumor. It is for people with locally advanced pancreatic cancer that has not spread, after they have already had standard chemotherapy.
This trial tests an experimental drug that targets tumors with a special protein detected by a PET scan. It may help treat certain cancers like breast, head and neck, pancreatic, or brain cancers that have grown despite prior treatment.
This early-stage trial tests a new radioactive drug (177Lu-DOTA-SNA040) designed to target a protein called Claudin18.2 found on certain cancer cells. The drug delivers radiation directly to tumors in patients with advanced gastric, pancreatic, or bile duct cancers that have stopped responding to standard treatments.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.